{"id":"iglar-u100","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":null,"_fixedAt":"2026-03-30T15:55:02.948587","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IGlar U100 (insulin glargine) is a recombinant human insulin analog designed to provide steady, long-acting basal insulin coverage for 24 hours. It binds to the insulin receptor on muscle, fat, and liver cells, facilitating glucose uptake and inhibiting hepatic glucose production. This maintains relatively constant insulin levels throughout the day, reducing fasting and basal hyperglycemia in diabetes patients.","oneSentence":"IGlar U100 is a long-acting basal insulin that binds to insulin receptors to lower blood glucose by promoting glucose uptake and storage in peripheral tissues.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:32:21.648Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"_fixedFields":["pubmed(21)"],"trialDetails":[{"nctId":"NCT07274644","phase":"PHASE4","title":"Effects of iGlarLixi Versus iGlar on Liver Fat Content in Patients With Type 2 Diabetes Mellitus Combined With Metabolic Dysfunction-associated Steatotic Liver Disease","status":"ENROLLING_BY_INVITATION","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2025-03-29","conditions":"Metabolic Dysfunction-Associated Steatotic Liver Disease, Diabetes Mellitus Type 2","enrollment":36},{"nctId":"NCT03723772","phase":"PHASE1","title":"A Research Study of How Different Doses of a New Medicine NNC0148-0287 C (Insulin 287) Work on the Blood Sugar in People With Type 1 Diabetes When it is Taken Once a Week","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2018-11-29","conditions":"Diabetes Mellitus, Type 1","enrollment":66},{"nctId":"NCT03689374","phase":"PHASE3","title":"A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2018-10-01","conditions":"Diabetes Mellitus, Type 2","enrollment":2274}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":21,"recentPublications":[{"date":"2025 Dec","pmid":"40840711","title":"Effectiveness and Safety of Early Insulin Glargine U100 and Glargine U300 Administration in the Management of Diabetic Ketoacidosis in Adults With Type 1 Diabetes Mellitus: A Randomized Clinical Trial.","journal":"Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists"},{"date":"2022 Sep","pmid":"35546450","title":"Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): A randomized, open-label, multinational, phase 3b trial.","journal":"Diabetes, obesity & metabolism"},{"date":"2021 Jul","pmid":"34052987","title":"Real-World Use of Insulin Glargine U100 and U300 in Insulin-Naïve Patients with Type 2 Diabetes Mellitus: DosInGlar Study.","journal":"Advances in therapy"},{"date":"2021 Jul","pmid":"33875485","title":"Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial.","journal":"Diabetes care"},{"date":"2021 Jul","pmid":"33875484","title":"A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100.","journal":"Diabetes care"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"IGlar U100","genericName":"IGlar U100","companyName":"Novo Nordisk A/S","companyId":"novo-nordisk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"IGlar U100 is a long-acting basal insulin that binds to insulin receptors to lower blood glucose by promoting glucose uptake and storage in peripheral tissues. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}